Current Report Filing (8-k)
March 26 2021 - 3:47PM
Edgar (US Regulatory)
0001035354
false
0001035354
2021-03-24
2021-03-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 24, 2021
Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-31326
|
|
84-1368850
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
950 Winter Street
Waltham, MA
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number,
including area code): (781) 577-5300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
ELOX
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 24, 2021, the Board of Directors (the “Board”)
of Eloxx Pharmaceuticals, Inc. (the “Company”) accepted the resignation of Mr. Stephen MacDonald as Vice President, Finance
and Accounting, and Treasurer, effective March 26, 2021.
Gary D. Rakers, 37, who joined with the Company in January 2020
and previously served as as Corporate Controller and Assistant Treasurer, was promoted to Executive Director, Finance and Accounting
and Corporate Controller. The Board appointed Mr. Rakers principal financial and accounting officer and Treasurer effective March
26, 2021. Mr. Rakers receives a base annual salary of $250,000, a target bonus of 28% and was granted 16,000 options to purchase
common stock of the Company at an exercise price equal to the fair market value of the Company’s common stock on the date of
his promotion. Prior to joining the Company, Mr. Rakers spent 6 years with Tesaro, Inc., prior to its acquisition by GSK, where he
held positions of increasing responsibility, culminating in the role of Associate Director of Technical Accounting and Operations.
Previously, Mr. Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche LLP, with a focus on the
healthcare and life sciences sector. Mr. Rakers will report to the Chief Executive Officer or his designee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELOXX PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Neil S. Belloff
|
|
Name:
|
Neil S. Belloff
|
|
Title:
|
Chief Operating Officer and General Counsel
|
Date: March 26, 2021
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jul 2023 to Jul 2024